Research programme: haemorrhagic fever virus inhibitors - Idenix/Institut Pasteur
Latest Information Update: 30 Dec 2021
Price :
$50 *
At a glance
- Originator Idenix Pharmaceuticals
- Developer Idenix Pharmaceuticals; Institut Pasteur
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ebola virus infections; Lassa fever
Most Recent Events
- 23 May 2006 No development reported - Preclinical for Ebola virus infections in France (unspecified route)
- 23 May 2006 No development reported - Preclinical for Ebola virus infections in USA (unspecified route)
- 23 May 2006 No development reported - Preclinical for Lassa fever in France (unspecified route)